Observational BMPR2-Activin Pathway Study in Group II Pulmonary Hypertension
Summary
The NIH registered a prospective observational study (NCT07537517) on ClinicalTrials.gov evaluating the BMPR2-activin signaling pathway in Group II pulmonary hypertension associated with left heart disease. The study will enroll 150 heart failure patients undergoing hemodynamic assessment with a 1-year follow-up, plus a nested substudy of 40 heart transplant candidates for vascular morphometric analysis. Results may inform PH-LHD classification, precision-medicine models, and targeted therapies such as activin inhibitors.
What changed
The NIH registered a new observational clinical study on ClinicalTrials.gov focusing on the BMPR2-activin signaling pathway in Group II pulmonary hypertension. The study will use a multimodal approach combining molecular biology, advanced cardiac imaging, and histology to determine the role of this pathway in development and regression of PH-LHD. A nested substudy involving 40 heart transplant candidates will include thoracic CT and histological correlation.
For clinical researchers and healthcare providers, this study represents an opportunity to contribute to understanding of pulmonary hypertension mechanisms and potential therapeutic targets. Patients with heart failure or pulmonary hypertension may benefit from increased awareness of ongoing research into disease classification and targeted therapies. The study's findings could influence future treatment approaches including activin inhibitors and refine transplant criteria.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.
Observational NCT07537517 Kind: OBSERVATIONAL Apr 17, 2026
Abstract
Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin.
Focusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology.
Its aim is to determine the role of the BMPR2-activin pathway in the development and regression of PH-LHD.
We will conduct a prospective observational study with 1-year follow-up in 150 heart failure patients of different etiologies undergoing hemodynamic assessment.
Clinical parameters, biomarkers, molecular profiles, and hemodynamic/echocardiographic variables will be analyzed.
A nested substudy in 40 heart transplant candidates will include thoracic CT for vascular morphometric analysis and histological correlation in explanted hearts versus healthy controls.
We will also assess reversibility of vascular remodeling one year after transplantation.
Results may redefine PH-LHD classification, enable phenotypic precision-medicine models, guide targeted therapies such as activin inhibitors, and refine transplant criteria in combined pulmonary hypertension.
Conditions: Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension (PH), Heart Failure
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.